SCHEMBL3370220

SCHEMBL3370220

CCOC(=O)/C(=C/c1cc(C)c(OCc2ccccc2)c(C)c1)OCC

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.54
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
ALDH1A1 P00352 2/20 0.45
LMNA P02545 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
PTPN1 P18031 1/20 0.41
HPGD P15428 1/20 0.41
KDM4E B2RXH2 2/20 0.41
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
FFAR4 Q5NUL3 1/20 0.39
GLRA1 P23415 1/20 0.39
PTGER1 P34995 1/20 0.39
PTGER4 P35408 1/20 0.39
PTGER3 P43115 1/20 0.39
PTGER2 P43116 1/20 0.39
MRGPRX4 Q96LA9 1/20 0.39
HSP90AA1 P07900 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2436006 0.88 NR1H4 (0.52) NR1H4KMT2AMEN1ALDH1A1LMNA
SCHEMBL2436007 0.88 NR1H4 (0.52) NR1H4KMT2AMEN1ALDH1A1LMNA
SCHEMBL3370127 0.85 NR1H4 (0.55) NR1H4KMT2AMEN1ALDH1A1LMNA
SCHEMBL12713672 0.82 NR1H4 (0.43) NR1H4KMT2AMEN1ALDH1A1KDM4E
SCHEMBL2807676 0.82 NR1H4 (0.79) NR1H4KMT2AMEN1ALDH1A1LMNA
SCHEMBL2804643 0.82 NR1H4 (0.79) NR1H4KMT2AMEN1ALDH1A1LMNA
SCHEMBL2804642 0.82 NR1H4 (0.79) NR1H4KMT2AMEN1ALDH1A1LMNA
SCHEMBL5381356 0.81 NR1H4 (0.62) NR1H4KMT2AMEN1ALDH1A1LMNA
SCHEMBL5381353 0.81 NR1H4 (0.62) NR1H4KMT2AMEN1ALDH1A1LMNA
SCHEMBL5485852 0.81 NR1H4 (0.62) NR1H4KMT2AMEN1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537091-B1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS HOFFMANN LA ROCHE (CH) 2010-10-06 EP disclosed
EP-1537091-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2005-06-08 EP disclosed
US-6809110-B2 NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID HOFFMANN-LA ROCHE INC. 2004-10-26 US disclosed
US-20040110807-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2004-06-10 US disclosed
WO-2004020420-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110807-A1 Thiazole derivatives SLC5A1, GPR119, INSR NR1H4 512/4885KMT2A 4113/4885MEN1 623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.